NCT06903377View on ClinicalTrials.gov

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

ZG005 for Injection

intravenous infusion

DRUG

Gecacitinib Hydrochloride Tablets

Oral

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY